Ribosomopathies and cancer: pharmacological implications

References

• Palade GE, Porter KR. Studies on the endoplasmic reticulum. I. Its identification in cells in situ. J Exp Med. 1954;100:641–656.
   Google Scholar
• Nürenberg-Goloub E, Tampé R. Ribosome recycling in mRNA translation, quality control, and homeostasis. Biol Chem. 2019;401(1):47–61.
   Google Scholar
• Kampen KR, Sulima SO, Vereecke S, et al., Hallmarks of ribosomopathies. Nucleic Acids Res. 2020;48(3): 1013–1028.
   Google Scholar
• Hellen CUT. Translation termination and ribosome recycling in eukaryotes. Cold Spring Harb Perspect Biol. 2018;10:a032656.
   Google Scholar
• Shirokikh NE, Preiss T. Translation initiation by cap- dependent ribosome recruitment: recent insights and open questions. Wiley Interdiscip Rev RNA. 2018;9:e1473.
   Google Scholar
• Stein KC, Frydman J. The stop-and-go traffic regulating protein biogenesis: how translation kinetics controls proteostasis. J Biol Chem. 2019;294:2076–2084.
   Google Scholar
• McStay B. Nucleolar organizer regions: genomic ‘dark matter’ requiring illumination. Genes Dev. 2016;30:1598–1610.
   Google Scholar
• Henras AK, Plisson-Chastang C, O’Donohue MF, et al. An overview of preribosomal RNA processing in eukaryotes. Wiley Interdiscip Rev RNA. 2015;6:225–242.
   Google Scholar
• Sørensen PD, Frederiksen S. Characterization of human 5S rRNA genes. Nucleic Acids Res. 1991;19:4147–4151.
   Google Scholar
• Wang W, Nag S, Zhang X, et al. Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev. 2015;35:225–285.
   Google Scholar
• Fromont-Racine M, Senger B, Saveanu C, et al. Ribosome assembly in eukaryotes. Gene. 2003;313:17–42.
   Google Scholar
• Golomb L, Volarevic S, Oren M. p53 and ribosome biogenesis stress: the essentials. FEBS Lett. 2014;588:2571–2579.
   Google Scholar
• Parks MM, Kurylo CM, Dass RA, et al. Variant ribosomal RNA alleles are conserved and exhibit tissue-specific expression. Sci Adv. 2018;4:eaao0665.
   Google Scholar
• Polikanov YS, Melnikov SV, Soll D, et al. Structural insights into the role of rRNA modifications in protein synthesis and ribosome assembly. Nat Struct Mol Biol. 2015;22:342–344.
   Google Scholar
• Sharma S, Lafontaine DLJ. ‘View from a bridge’: a new perspective on eukaryotic rRNA base modification. Trends Biochem Sci. 2015;40:560–575.
   Google Scholar
• Natchiar SK, Myasnikov AG, Kratzat H, et al. Visualization of chemical modifications in the human 80S ribosome structure. Nature. 2017;551:472–477.
   Google Scholar
• Roundtree IA, Evans ME, Pan T, et al. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187–1200.
   Google Scholar
• Schosserer M, Minois N, Angerer TB, et al. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat Commun. 2015;6:6158.
   Google Scholar
• Sloan KE, Warda AS, Sharma S, et al. Tuning the ribosome: the influence of rRNA modification on eukaryotic ribosome biogenesis and function. RNA Biol. 2017;14:1138–1152.
   Google Scholar
• Sharma S, Hartmann JD, Watzinger P, et al. A single N1-methyladenosine on the large ribosomal subunit rRNA impacts locally its structure and the translation of key metabolic enzymes. Sci Rep. 2018;8:11904.
   Google Scholar
• Bellodi C, Kopmar N, Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J. 2010;29:1865–1876.
   Google Scholar
• Truitt ML, Ruggero D. New frontiers in translational control of the cancer genome. Nat Rev Cancer. 2017;17:332.
   Google Scholar
• Doll A, Grzeschik KH. Characterization of two novel genes, WBSCR20 and WBSCR22, deleted in Williams-Beuren syndrome. Cytogenet Cell Genet. 2001;95:20–27.
   Google Scholar
• Armistead J, Khatkar S, Meyer B, et al. Mutation of a gene essential for ribosome biogenesis, EMG1, causes Bowen-Conradi syndrome. Am J Hum Genet. 2009;84:728–739.
   Google Scholar
• Montanaro L, Treré D, Derenzini M. Nucleolus, ribosomes, and cancer. Am J Pathol. 2008;173:301–310.
   Google Scholar
• Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115:3196–3205.
   Google Scholar
• Armistead J, Triggs-Raine B. Diverse diseases from a ubiquitous process: the ribosomopathy paradox. FEBS Lett. 2014;588:1491–1500.
   Google Scholar
• Danilova N, Gazda HT. Ribosomopathies: how a common root can cause a tree of pathologies. Dis Model Mech. 2015;8:1013–1026.
   Google Scholar
• Wilson DN, Doudna Cate JH. The structure and function of the eukaryotic ribosome. Cold Spring Harb Perspect Biol. 2012;4(5):a011536.
   Google Scholar
• Doudna JA, Rath VL. Structure and function of the eukaryotic ribosome: the next frontier. Cell. 2002;109(2):153–156.
   Google Scholar
• Fatica A, Tollervey D. Making ribosomes. Curr Opin Cell Biol. 2002;14(3):313–318.
   Google Scholar
• O’Donohue MF, Choesmel V, Faubladier M, et al. Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits. J Cell Biol. 2010;190(5):853–866.
   Google Scholar
• Rahhal R, Seto E. Emerging roles of histone modifications and HDACs in RNA splicing. Nucleic Acids Res. 2019;47(10):4911–4926.
   Google Scholar
• Smith MC, Mader MM, Cook JA, et al. Characterization of LY3023414, a novel PI3K/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth. Mol Cancer Ther. 2016;15:2344–2356.
   Google Scholar
• Russell J, Zomerdijk JC. RNA-polymerase-I-directed rDNA transcription, life and works. Trends Biochem Sci. 2005;30:87–96.
   Google Scholar
• Albert B, Perez-Fernandez J, Léger-Silvestre I, et al. Regulation of ribosomal RNA production by RNA polymerase I: does elongation come first? Genet Res Int. 2012;2012:276948.
   Google Scholar
• Greber BJ, Gerhardy S, Leitner A, et al. Insertion of the biogenesis factor rei1 probes the ribosomal tunnel during 60S maturation. Cell. 2016;164:1–12.
   Google Scholar
• Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates myc-mediated transcription by phosphorylating and promoting the degradation of mad1. Proc Natl Acad Sci USA. 2008;105:6584–6589.
   Google Scholar
• Mendoza MC, Er EE, The Ras-ERK BJ. and PI3KmTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36:320–328.
   Google Scholar
• Mayer C, Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene. 2006;25:6384–6391.
   Google Scholar
• Woiwode A, Johnson SA, Zhong S, et al. PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex. Mol Cell Biol. 2008;28:4204–4214.
   Google Scholar
• Kantidakis T, Ramsbottom BA, Birch JL, et al. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci USA. 2010;107:11823–11828.
   Google Scholar
• Watkins NJ, Bohnsack MT. The box C/D and H/ACA snoRNPs: key players in the modification, processing and the dynamic folding of ribosomal RNA. Wiley Interdiscip Rev RNA. 2012;3:397–414.
   Google Scholar
• Cong R, Das S, Ugrinova I, et al. Interaction of nucleolin with ribosomal RNA genes and its role in RNA polymerase I transcription. Nucleic Acids Res. 2012;40:9441–9454.
   Google Scholar
• Ginisty H, Amalric F, Bouvet P. Nucleolin functions in the first step of ribosomal RNA processing. EMBO J. 1998;17:1476–1486.
   Google Scholar
• Roger B, Moisand A, Amalric F, et al. Nucleolin provides a link between RNA polymerase I transcription and pre-ribosome assembly. Chromosoma. 2003;111:399–407.
   Google Scholar
• Ginisty H, Serin G, Ghisolfi-Nieto L, et al. Interaction of nucleolin with an evolutionarily conserved pre-ribosomal RNA sequence is required for the assembly of the primary processing complex. J Biol Chem. 2000;275:18845–18850.
   Google Scholar
• Murano K, Okuwaki M, Hisaoka M, et al. Transcription regulation of the rRNA gene by a multifunctional nucleolar protein, B23/nucleophosmin, through its histone chaperone activity. Mol Cell Biol. 2008;28:3114–3126.
   Google Scholar
• Savkur RS, Olson MO. Preferential cleavage in preribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 1998;26:4508–4515.
   Google Scholar
• Yu Y, Maggi LB Jr, Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 2006;26:3798–3809.
   Google Scholar
• LBJr M, Kuchenruether M, Dadey DY, et al. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the mammalian ribosome. Mol Cell Biol. 2008;28:7050–7065.
   Google Scholar
• Box JK, Paquet N, Adams MN, et al. Nucleophosmin: from structure and function to disease development. BMC Mol Biol. 2016;17:19.
   Google Scholar
• Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell. 2003;12:1151–1164.
   Google Scholar
• Kerr LE, Birse-Archbold JL, Short DM, et al. Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death. Oncogene. 2007;26:2554–2562.
   Google Scholar
• Henras AK, Soudet J, Gérus M, et al. The post-transcriptional steps of eukaryotic ribosome biogenesis. Cell Mol Life Sci. 2008;65:2334–2359.
   Google Scholar
• Shenoy N, Kessel R, Bhagat TD, et al. Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol. 2012;5:32.
   Google Scholar
• Boon K, Caron HN, van Asperen R, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001;20(6):1383–1393.
   Google Scholar
• Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3(3):179–192.
   Google Scholar
• Ferreira R, JSJr S, Panov KI, et al. Targeting the RNA polymerase I transcription for cancer therapy comes of age. Cells. 2020;9:266.
   Google Scholar
• Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22:51–65.
   Google Scholar
• Wei T, Najmi SM, Liu H, et al. Small-molecule targeting of RNA polymerase I activates a conserved transcription elongation checkpoint. Cell Rep. 2018;23:404–414.
   Google Scholar
• Kusnadi EP, Trigos AS, Cullinane C, et al., Reprogrammed mRNA translation drives metabolic response to therapeutic targeting of ribosome biogenesis. EMBO J. 39(21): e105111. 2020.
   Google Scholar
• Xu H, Di Antonio M, McKinney S, et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nat Commun. 2017;8:14432.
   Google Scholar
• Drygin D, Lin A, Bliesath J, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011;71:1418–1430.
   Google Scholar
• Peltonen K, Colis L, Liu H, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014;25:77–90.
   Google Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398.
   Google Scholar
• Bharti AC, Donato N, Singh S, et al. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101:1053–1062.
   Google Scholar
• Jutooru I, Chadalapaka G, Lei P, et al. Inhibition of NF kappa B and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem. 2010;285:25332–25344.
   Google Scholar
• Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 1999;59:597–601.
   Google Scholar
• Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998;17:173–178.
   Google Scholar
• Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep. 2012;6:1267–1270.
   Google Scholar
• Yun JH, Park YG, Lee KM, et al. Curcumin induces apoptotic cell death via Oct4 inhibition and GSK-3beta activation in NCCIT cells. Mol Nutr Food Res. 2015;59:1053–1062.
   Google Scholar
• Xu Y, Wu Y, Wang L, et al. Identification of curcumin as a novel natural inhibitor of rDNA transcription. Cell Cycle. 2020;19(23):3362–3374.
   Google Scholar
• Andrews WJ, Panova T, Normand C, et al. Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. J Biol Chem. 2013;288:4567–4582.
   Google Scholar
• Brown RV, Danford FL, Gokhale V, et al. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem. 2011;286:41018–41027.
   Google Scholar
• Likovsky Z, Peterka M, Peterkova R. Drug-induced changes of rRNA biosynthesis – a marker of toxic damage to embryonal cell population. Funct Dev Morphol. 1993;3:3–9.
   Google Scholar
• Rey JP, Scott R, Muller H. Induction and removal of interstrand crosslinks in the ribosomal RNA genes of lymphoblastoid cell lines from patients with Fanconi anemia. Mutat Res. 1993;289:171–180.
   Google Scholar
• Mathijssen RH, Loos WJ, Verweij J, et al. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets. 2002;2(2):103–123.
   Google Scholar
• Burger K, Mühl B, Harasim T, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem. 2010;285:12416–12425.
   Google Scholar
• Gilder AS, Do PM, Carrero ZI, et al. Coilin participates in the suppression of RNA polymerase I in response to cisplatin-induced DNA damage. Mol Biol Cell. 2011;22:1070–1079.
   Google Scholar
• Haaf T, Ward DC. Inhibition of RNA polymerase II transcription causes chromatin decondensation, loss of nucleolar structure, and dispersion of chromosomal domains. Exp Cell Res. 1996;224:163–173.
   Google Scholar
• Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23:461–471.
   Google Scholar
• Sutton EC, McDevitt CE, Prochnau JY, et al. Nucleolar stress induction by oxaliplatin and derivatives. J Am Chem Soc. 2019;141(46):18411–18415.
   Google Scholar
• Peyroche G, Milkereit P, Bischler N, et al. The recruitment of RNA polymerase I on rDNA is mediated by the interaction of the A43 subunit with Rrn3. EMBO J. 2000;19:5473–5482.
   Google Scholar
• Miller G, Panov KI, Friedrich JK, et al. hRRN3 is essential in the SL1-mediated recruitment of RNA polymerase I to rRNA gene promoters. EMBO J. 2001;20:1373–1382.
   Google Scholar
• Milkereit P, Tschochner H. A specialized form of RNA polymerase I, essential for initiation and growth-dependent regulation of rRNA synthesis, is disrupted during transcription. EMBO J. 1998;17:3692–3703.
   Google Scholar
• Gnanasundram SV, Pyndiah S, Daskalogianni C, et al. PI3K_ activates E2F1 synthesis in response to mRNA translation stress. Nat Commun. 2017;8:2103.
   Google Scholar
• Rothblum K, Hu Q, Penrod Y, et al. Selective inhibition of rDNA transcription by a small- molecule peptide that targets the interface between RNA polymerase I and Rrn3. Mol Cancer Res. 2014;12:1586–1596.
   Google Scholar
• Pertschy B, Zisser G, Schein H, et al. Diazaborine treatment of yeast cells inhibits maturation of the 60s ribosomal subunit. Mol Cell Biol. 2004;24:6476–6487.
   Google Scholar
• Kawashima SA, Chen Z, Aoi Y, et al. Potent, reversible, and specific chemical inhibitors of eukaryotic ribosome biogenesis. Cell. 2016;167:512–524.
   Google Scholar
• Kofler L, Prattes M, Bergler H. Inhibiting eukaryotic ribosome biogenesis: mining new tools for basic research and medical applications. Microb Cell. 2019;6(10):491–493.
   Google Scholar
• Awad D, Prattes M, Kofler L, et al. Inhibiting eukaryotic ribosome biogenesis. BMC Biol. 2019;17:46.
   Google Scholar
• Shelton J, Lu X, Hollenbaugh JA, et al. Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs. Chem Rev. 2016;116(23):14379–14455.
   Google Scholar
• Caro-Vegas C, Bailey A, Bigi R, et al. Targeting mTOR with MLN0128 overcomes rapamycin and chemoresistant primary effusion lymphoma. MBio. 2019;10:e02871–18.
   Google Scholar
• Kwon Y, Cha J, Chiang J, et al. A chemogenomic approach to understand the antifungal action of Lichen derived vulpinic acid. J Appl Microbiol. 2016;121(6):1580–1591.
   Google Scholar
• Rajagopalan PTR, Zhang Z, McCourt L, et al. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci. 2002;99(21):13481–13486.
   Google Scholar
• Albrecht LV, Bui MH, Robertis EMD. Canonical Wnt is inhibited by targeting one-carbon metabolism through methotrexate or methionine deprivation. Proc Natl Acad Sci. 2019;116(8):2987–2995.
   Google Scholar
• Bidou L, Allamand V, Rousset JP, et al. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med. 2012;18:679–688.
   Google Scholar
• Shi Y, Zhai H, Wang X, et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp Cell Res. 2004;296(2):337–346.
   Google Scholar
• Speth J, Shi Y, Pan Y, et al. Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells. Cancer Biol Ther. 2005;4(2):242–247.
   Google Scholar
• Huang XP, Zhao CX, Li QJ, et al. Alteration of RPL14 in squamous cell carcinomas and preneoplastic lesions of the esophagus. Gene. 2006;366(1):161–168.
   Google Scholar
• Kim JH, You KR, Kim IH, et al. Over-expression of the ribosomal protein L36a gene is associated with cellular proliferation in hepatocellular carcinoma. Hepatology. 2004;39(1):129–138.
   Google Scholar
• Wang H, Zhao LN, Li KZ, et al. Overexpression of ribosomal protein L15 is associated with cell proliferation in gastric cancer. BMC Cancer. 2006;6:91.
   Google Scholar
• Gou Y, Shi Y, Zhang Y, et al. Ribosomal protein L6 promotes growth and cell cycle progression through upregulating cyclin E in gastric cancer cells. Biochem Biophys Res Commun. 2010;393(4):788–793.
   Google Scholar
• Kobayashi T, Sasaki Y, Oshima Y, et al. Activation of the ribosomal protein L13 gene in human gastrointestinal cancer. Int J Mol Med. 2006;18(1):161–170.
   Google Scholar
• Pogue-Geile K, Geiser JR, Shu M, et al. Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol. 1991;11(8):3842–3849.
   Google Scholar
• Kasai H, Nadano D, Hidaka E, et al. Differential expression of ribosomal proteins in human normal and neoplastic colorectum. J Histochem Cytochem. 2003;51(5):567–574.
   Google Scholar
• Ohkia A, Hu Y, Wang M, et al. Evidence for prostate cancer-associated diagnostic marker-1: immunohistochemistry and in situ hybridization studies. Clin Cancer Res. 2004;10(7):2452–2458.
   Google Scholar
• Wang M, Hu YJ, Stearns ME. RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res. 2009;28:6.
   Google Scholar
• Wang Q, Yang C, Zhou J, et al. Cloning and characterization of full-length human ribosomal protein L15 cDNA which was overexpressed in esophageal cancer. Gene. 2001;263(1–2):205–209.
   Google Scholar
• Kim SH, Jang YH, Chau GC, et al. Prognostic significance and function of phosphorylated ribosomal protein S6 in esophageal squamous cell carcinoma. Mod Pathol. 2013;26(3):327–335.
   Google Scholar
• Yang M, Sun H, Wang H, et al. Down-regulation of ribosomal protein L22 in non-small cell lung cancer. Med Oncol. 2013;30(3):646.
   Google Scholar
• McDonald JM, Pelloski CE, Ledoux A, et al. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 2008;14(23):7832–7837.
   Google Scholar
• Wang S, Huang J, He J, et al. RPL41, a small ribosomal peptide deregulated in tumors, is essential for mitosis and centrosome integrity. Neoplasia. 2010;12(3):284–293.
   Google Scholar
• Zheng SE, Yao Y, Dong Y, et al. Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol. 2009;135(8):1025–1031.
   Google Scholar
• Hagner PR, Mazan-Mamczarz K, Dai B, et al. Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5’ terminal oligopyrimidine tract. Oncogene. 2011;30(13):1531–1541.
   Google Scholar
• Wu LY, Li X, Xu F, et al. Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34(+) cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine. Ann Hematol. 2012;91(10):1547–1554.
   Google Scholar
• Tsofack SP, Meunier L, Sanchez L, et al. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis. BMC Cancer. 2013;13:303.
   Google Scholar
• Simsek D, Barna M. An emerging role for the ribosome as a nexus for post-translational modifications. Curr Opin Cell Biol. 2017;45:92–101.
   Google Scholar
• Emmott E, Jovanovic M, Ribosome Stoichiometry: SN. From Form to Function. Trends Biochem Sci. 2019;44:95–109.
   Google Scholar
• Li C, Ge M, Yin Y, et al. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. Mol Cell Biochem. 2012;370(1–2):127–139.
   Google Scholar
• Wu Q, Gou Y, Wang Q, et al. Downregulation of RPL6 by siRNA inhibits proliferation and cell cycle progression of human gastric cancer cell lines. PLoS One. 2011;6(10):e26401.
   Google Scholar
• Bee A, Brewer D, Beesley C, et al. siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer. PLoS One. 2011;6(7):e22672.
   Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49–53.
   Google Scholar
• Bursac S, Brdovcak MC, Donati G, et al. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim Biophys Acta-Mol Basis Dis. 2014; 1842: 817–830.
   Google Scholar
• James A, Wang Y, Raje H, et al. Nucleolar stress with and without p53. Nucleus. 2014;5:402–426.
   Google Scholar
• Orsolic I, Jurada D, Pullen N, et al. The relationship between the nucleolus and cancer: current evidence and emerging paradigms. Semin Cancer Biol. 2016;37(38):36–50.
   Google Scholar
• Holmberg Olausson K, Nistér M, Lindström M, et al. p53 -dependent and -independent nucleolar stress responses. Cells. 2012;1:774–798.
   Google Scholar
• Kappel L, Loibl M, Zisser G, et al. Rlp24 activates the AAA-ATPase Drg1 to initiate cytoplasmic pre-60S maturation. J Cell Biol. 2012;199:771–782.
   Google Scholar
• Bassler J, Kallas M, Pertschy B, et al. The AAA-ATPase Rea1 drives removal of biogenesis factors during multiple stages of 60S ribosome assembly. Mol Cell. 2010;38:712–721.
   Google Scholar
• Anderson DJ, Le Moigne R, Djakovic S, et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015;28(5):653–665.
   Google Scholar
• Firestone AJ, Weinger JS, Maldonado M, et al. Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature. 2012;484(7392):125–129.
   Google Scholar
• Lindstrom MS. NPM1/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int. 2011;2011:195209.
   Google Scholar
• Qi W, Shakalya K, Stejskal A, et al. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008;27:4210–4220.
   Google Scholar
• Wulff JE, Siegrist R, Myers AG. The natural product avrainvillamide binds to the oncoprotein nucleophosmin. J Am Chem Soc. 2007;129(46):14444–14451.
   Google Scholar
• Ertekin E, Gencturk E, Kasim M, et al. A drug repurposing and protein–protein interaction network study of ribosomopathies using yeast as a model system. OMICS. 2020;24
   Google Scholar
• Nag S, Qin JJ, Srivenugopal K, et al. The MDM2-p53 pathway revisited. J Biomed Res. 2013;27(4):254–271.
   Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275–283.
   Google Scholar
• Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413–431.
   Google Scholar
• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749–758.
   Google Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6(12):909–923.
   Google Scholar
• Crighton D, Woiwode A, Zhang C, et al. p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO J. 2003;22:2810–2820.
   Google Scholar
• Juven T, Barak Y, Zauberman A, et al. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene. 1993;8(12):3411–3416.
   Google Scholar
• Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7A):1126–1132.
   Google Scholar
• Barak Y, Juven T, Haffner R, et al. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12(2):461–468.
   Google Scholar
• Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857–860.
   Google Scholar
• Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–299.
   Google Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303.
   Google Scholar
• Honda R, Tanaka H, Oncoprotein YH. MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25–27.
   Google Scholar
• Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003;13:49–58.
   Google Scholar
• Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92(6):725–734.
   Google Scholar
• Weber JD, Taylor LJ, Roussel MF, et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999;1(1):20–26.
   Google Scholar
• Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16(5):369–377.
   Google Scholar
• Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget. 2011;2(3):234–238.
   Google Scholar
• Lohrum MAE, Ludwig RL, Kubbutat MHG, et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 2003;3:577–587.
   Google Scholar
• Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23:8902–8912.
   Google Scholar
• Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004;279:44475–44482.
   Google Scholar
• Liu Y, Deisenroth C, Zhang Y. Zhang Y. RP-MDM2-p53 pathway: linking ribosomal biogenesis and tumor surveillance. Trends Cancer. 2016;2:191–204.
   Google Scholar
• Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53n pathway. Oncogene. 2010;29:4253–4260.
   Google Scholar
• Penzo M, Montanaro L, Treré D, et al., The ribosome biogenesis-cancer connection. Cells. 8(1): 55. 2019.
   Google Scholar
• Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003;22:6068–6077.
   Google Scholar
• Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5:465–475.
   Google Scholar
• Dhar SK, St Clair DK. Nucleophosmin blocks mitochondrial localization of p53 and apoptosis. J Biol Chem. 2009;284:16409–16418.
   Google Scholar
• Sun XX, Dai MS, Lu H. 5-fluorouracil activation of p53 involves an MDM2- ribosomal protein interaction. J Biol Chem. 2007;282:8052–8059.
   Google Scholar
• Sun XX, Dai MS, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem. 2008;283:12387–12392.
   Google Scholar
• Donati G, Bertoni S, Brighenti E, et al. The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells. Oncogene. 2011;30(29):3274–3288.
   Google Scholar
• Balch WE, Morimoto RI, Dillin A, et al. Manipulating proteostasis for disease intervention. Science. 2008;319:916–919.
   Google Scholar
• Dai MS, Zeng SX, Jin Y, et al. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 2004;24:7654–7668.
   Google Scholar
• Espinoza JA, Zisi A, Kanellis DC, et al. The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity. Cell Death Differ. 2020;27:773–789.
   Google Scholar
• Scala F, Brighenti E, Govoni M, et al. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate. Oncogene. 2016;35(8):977–989.
   Google Scholar
• Carpenter RL, Gokmen-Polar Y. HSF1 as a cancer biomarker and therapeutic target. Curr Cancer Drug Targets. 2019;19:515–524.
   Google Scholar
• Wu CT, Lin TY, Hsu HY, et al. Ling Zhi-8 mediates p53-dependent growth arrest of lung cancer cells proliferation via the ribosomal protein S7-MDM2-p53 pathway. Carcinogenesis. 2011;32(12):1890–1896.
   Google Scholar
• Donati G, Montanaro L, Derenzini M. Ribosome biogenesis and control of cell proliferation: p53 is not alone. Cancer Res. 2012;72:1602–1607.
   Google Scholar
• Lindstrom MS, Jin A, Deisenroth C, et al. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol. 2007;27(3):1056–1068.
   Google Scholar
• Kondoh N, Shuda M, Tanaka K, et al. Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma. Anticancer Res. 2001;21(4A):2429–2433.
   Google Scholar
• Russo A, Russo G. Ribosomal proteins control or bypass p53 during nucleolar stress. Int J Mol Sci. 2017;18(1):140.
   Google Scholar
• Derenzini M, Montanaro L, Trere D. Ribosome biogenesis and cancer. Acta Histochem. 2017;119:190–197.
   Google Scholar
• Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, et al. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem Soc Symp. 2006;73:141–154.
   Google Scholar
• van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10:301–309.
   Google Scholar
• Yin Y, Hua H, Li M, et al. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res. 2016;26:46–65.
   Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976.
   Google Scholar
• Stefanovsky VY, Pelletier G, Hannan R, et al. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell. 2001;8:1063–1073.
   Google Scholar
• Stefanovsky V, Langlois F, Gagnon-Kugler T, et al. Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling. Mol Cell. 2006;21:629–639.
   Google Scholar
• Grummt I. Wisely chosen paths–regulation of rRNA synthesis: delivered on 30 June 2010 at the 35th FEBS congress in Gothenburg, Sweden. FEBS J. 2010;277:4626–4639.
   Google Scholar
• Gentilella A, Kozma SC, Thomas G. A liaison between mTOR signaling, ribosome biogenesis and cancer. Biochim Biophys Acta. 2015;1849:812–820.
   Google Scholar
• Zinzalla V, Stracka D, Oppliger W, et al. Activation of mTORC2 by association with the ribosome. Cell. 2011;144:757–768.
   Google Scholar
• Dienstmann R, Rodon J, Serra V, et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13:1021–1031.
   Google Scholar
• Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther. 2015;15:51–68.
   Google Scholar
• Janku F, Wheler JJ, Naing A, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013;73(1):276–284.
   Google Scholar
• Ribosomal Protein MO. S6 phosphorylation: four decades of research. Int Rev Cell Mol Biol. 2015;320:41–73.
   Google Scholar
• Sun CK, Zhang F, Xiang T, et al. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. Oncotarget. 2014;5:3375–3385.
   Google Scholar
• Hsieh AC, Costa M, Zollo O, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2009;17:249–261.
   Google Scholar
• Vadivel Gnanasundram S, Translation Stress FR. Regulates ribosome synthesis and cell proliferation. Int J Mol Sci. 2018;19(12):3757.
   Google Scholar
• Burris HA, Kurkjian CD, Hart L. 3rd, Kurkjian CD, hart L, et al. TAK- 228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2017;80:261–273.
   Google Scholar
• Slotkin EK, Patwardhan PP, Vasudeva SD, et al. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Mol Cancer Ther. 2015;14:395–406.
   Google Scholar
• Gökmen-Polar Y, Liu Y, Toroni RA, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat. 2012;136:673–682.
   Google Scholar
• Rashid MM, Lee H, Jung BH. Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1072:244–251.
   Google Scholar
• Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38.
   Google Scholar
• Guichard SM, Curwen J, Bihani T, et al. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol Cancer Ther. 2015;14:2508–2518.
   Google Scholar
• Jordan NJ, Dutkowski CM, Barrow D, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res. 2014;16:R12.
   Google Scholar
• Chiarini F, Evangelisti C, McCubrey JA, et al. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci. 2015;36:124–135.
   Google Scholar
• Zaidi AH, Kosovec JE, Matsui D, et al. PI3K/mTOR dual inhibitor, LY3023414, demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model. Ann Surg. 2017;266:91–98.
   Google Scholar
• Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014;13:1078–1091.
   Google Scholar
• Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.
   Google Scholar
• Beaufils F, Cmiljanovic N, Cmiljanovic V, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2- amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology. J Med Chem. 2017;60:7524–7538.
   Google Scholar
• Brandt C, Hillmann P, Noack A, et al. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology. 2018;140:107–120.
   Google Scholar
• Venkatesan AM, Dehnhardt CM, Delos Santos E, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5’-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010;53:2636–2645.
   Google Scholar
• Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett. 2010;1:39–43.
   Google Scholar
• Hua H, Zhang H, Kong Q, et al. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. 2019;39:114–145.
   Google Scholar
• Boyle KA, Van Wickle J, Hill RB, et al. Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J Biol Chem. 2018;293:14891–14904.
   Google Scholar
• Ling S, Xie H, Yang F, et al. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol. 2017;10:59.
   Google Scholar
• Fan QW, Cheng CK, Nicolaides TP, et al. A dual phosphoinositide-3-kinase a/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007;67:7960–7965.
   Google Scholar
• Rehan M, Saleem M. Anticancer compound XL765 as PI3K/mTOR dual inhibitor: a structural insight into the inhibitory mechanism using computational approaches. PLoS One. 2019;14(6):e0219180.
   Google Scholar
• Bhatt AP, Bhende PM, Sin SH, et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010;115(22):4455–4463.
   Google Scholar
• Chen X, Zhao M, Hao M, et al. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol Cancer Res. 2013;11(10):1269–1278.
   Google Scholar
• Hu X, Xia M, Wang J, et al. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. Biomed Pharmacother. 2020;129:110397.
   Google Scholar
• Bhat M, Robichaud N, Hulea L, et al. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14:261–278.
   Google Scholar
• Harper JW, Bennett EJ. Proteome complexity and the forces that drive proteome imbalance. Nature. 2016;537:328–338.
   Google Scholar
• Tubbs A, Endogenous NA. DNA damage as a source of genomic instability in cancer. Cell. 2017;168:644–656.
   Google Scholar
• Skrott Z, Mistrik M, Andersen KK, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552:194–199.
   Google Scholar
• Santagata S, Mendillo ML, Tang YC, et al. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science. 2013;341:1238303.
   Google Scholar
• Valvezan AJ, Turner M, Belaid A, et al. mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability. Cancer Cell. 2017;32(5):624–638.
   Google Scholar
• Xu Y, Ruggero D. The role of translation control in tumorigenesis and its therapeutic implications. Annu Rev Cancer Biol. 2019;4:437–457.
   Google Scholar
• Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18:51–63.
   Google Scholar
• Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169–175.
   Google Scholar
• Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006;79(6):1110–1118.
   Google Scholar
• Cmejla R, Cmejlova J, Handrkova H, et al. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat. 2007;28(12):1178–1182.
   Google Scholar
• Song MJ, Yoo EH, Lee KO, et al. A novel initiation codon mutation in the ribosomal protein S17 gene (RPS17) in a patient with Diamond-Blackfan anemia. Pediatr Blood Cancer. 2010;54(4):629–631.
   Google Scholar
• Cmejla R, Cmejlova J, Handrkova H, et al. Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia. Hum Mutat. 2009;30(3):321–327.
   Google Scholar
• Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond Blackfan anemia patients. Am J Hum Genet. 2008;83(6):769–780.
   Google Scholar
• Gazda HT, Preti M, Sheen MR, et al. Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in Diamond-Blackfan anemia. Hum Mutat. 2012;33(7):1037–1044.
   Google Scholar
• Farrar JE, Nater M, Caywood E, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood. 2008;112(5):1582–1592.
   Google Scholar
• Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010;86(2):222–228.
   Google Scholar
• Landowski M, O’Donohue MF, Buros C, et al. Novel deletion of RPL15 identified by array-comparative genomic hybridization in Diamond-Blackfan anemia. Hum Genet. 2013;132(11):1265–1274.
   Google Scholar
• Barlow JL, Drynan LF, Trim NL, et al. New insights into 5q- syndrome as a ribosomopathy. Cell Cycle. 2010;9(21):4286–4293.
   Google Scholar
• Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med. 2008;14(2):125–133.
   Google Scholar
• Sakai D, Trainor PA. Treacher Collins syndrome: unmasking the role of Tcof1/treacle. Int J Biochem Cell Biol. 2009;41(6):1229–1232.
   Google Scholar
• Ganapathi KA, Shimamura A. Ribosomal dysfunction and inherited marrow failure. Br J Haematol. 2008;141(3):376–387.
   Google Scholar
• Burroughs L, Woolfrey A, Shimamura A. Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin North Am. 2009;23(2):233–248.
   Google Scholar
• Boocock GR, Morrison JA, Popovic M, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet. 2003;33(1):97–101.
   Google Scholar
• Weis F, Giudice E, Churcher M, et al. Mechanism of eIF6 release from the nascent 60S ribosomal subunit. Nat Struct Mol Biol. 2015;22(11):914–919.
   Google Scholar
• Finch AJ, Hilcenko C, Basse N, et al. Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes Dev. 2011;25(9):917–929.
   Google Scholar
• Morini J, Babini G, Mariotti L, et al. Radiosensitivity in lymphoblastoid cell lines derived from Shwachman–Diamond syndrome patients. Radiat Prot Dosimetry. 2015;166(1–4):95–100.
   Google Scholar
• Toiviainen-Salo S, Mäyränpää MK, Durie PR, et al. Shwachman-Diamond syndrome is associated with low-turnover osteoporosis. Bone. 2007;41(6):965–972.
   Google Scholar
• Qiu XB, Shao YM, Miao S, et al. The diversity of the DnaJ/ Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci. 2006;63(22):2560–2570.
   Google Scholar
• Quelle DE, Zindy F, Ashmun RA, et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000.
   Google Scholar
• Tikoo S, Sengupta S. Time to bloom. Genome Integr. 2010;1:14.
   Google Scholar
• Shiratori M, Suzuki T, Itoh C, et al. WRN helicase accelerates the transcription of ribosomal RNA as a component of an RNA polymerase I-associated complex. Oncogene. 2002;21:2447–2454.
   Google Scholar
• Rossi ML, Ghosh AK, Bohr VA. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair (Amst). 2010;9:331–344.
   Google Scholar
• Natale V. A comprehensive description of the severity groups in Cockayne syndrome. Am J Med Genet A. 2011;155A:1081–1095.
   Google Scholar
• Laugel V, Dalloz C, Durand M, et al. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. Hum Mutat. 2010;31:113–126.
   Google Scholar
• Bradsher J, Auriol J, Proietti de Santis L, et al. CSB is a component of RNA pol I transcription. Mol Cell. 2002;10:819–829.
   Google Scholar
• Laumonnier F, Holbert S, Ronce N, et al. Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J Med Genet. 2005;42:780–786.
   Google Scholar
• Lisik MZ, Sieron AL. X-linked mental retardation. Med Sci Monit. 2008;14:RA221–RA229.
   Google Scholar
• Dawson MA, Bannister AJ. Demethylases go mental. Mol Cell. 2010;38:155–157.
   Google Scholar
• Kleine-Kohlbrecher D, Christensen J, Vandamme J, et al. A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol Cell. 2010;38:165–178.
   Google Scholar
• Loenarz C, Ge W, Coleman ML, et al. PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an Nepsilondimethyl lysine demethylase. Hum Mol Genet. 2010;19:217–222.
   Google Scholar
• Bose T, Lee KK, Lu S, et al. Cohesin proteins promote ribosomal RNA production and protein translation in yeast and human cells. PLoS Genet. 2012;8e:1002749.
   Google Scholar
• Feng W, Yonezawa M, Ye J, et al. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat Struct Mol Biol. 2010;17:445–450.
   Google Scholar
• Ide S, Miyazaki T, Maki H, et al. Abundance of ribosomal RNA gene copies maintains genome integrity. Science. 2010;327:693–696.
   Google Scholar
• Velkova A, Carvalho MA, Johnson JO, et al. Identification of Filamin A as a BRCA1-interacting protein required for efficient DNA repair. Cell Cycle. 2010;9:1421–1433.
   Google Scholar
• Najib S, Saint-Laurent N, Esteve JP, et al. A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. Mol Cell Biol. 2012;32:1004–1016.
   Google Scholar
• Zhou AX, Hartwig JH, Akyurek LM. Filamins in cell signaling, transcription and organ development. Trends Cell Biol. 2010;20:113–123.
   Google Scholar
• Yuan Y, Shen Z. Interaction with BRCA2 suggests a role for filamin-1 (hsFLNa) in DNA damage response. J Biol Chem. 2001;276:48318–48324.
   Google Scholar
• Yue J, Lu H, Liu J, et al. Filamin-A as a marker and target for DNA damage based cancer therapy. DNA Repair (Amst). 2012;11:192–200.
   Google Scholar
• Deng W, Lopez-Camacho C, Tang JY, et al. Cytoskeletal protein filamin A is a nucleolar protein that suppresses ribosomal RNA gene transcription. Proc Natl Acad Sci. U S A. 2012; 109: 1524–1529.
   Google Scholar
• Quin JE, Devlin JR, Cameron D, et al. Targeting the nucleolus for cancer intervention. Biochim Biophys Acta. 2014;1842(6):802–816.
   Google Scholar
• Boulon S, Westman BJ, Hutten S, et al. The nucleolus under stress. Mol Cell. 2010;40:216–227.
   Google Scholar
• Siebert A, Prejs M, Cholewinski G, et al. New analogues of mycophenolic acid. Mini Rev Med Chem. 2017;17(9):734–745.
   Google Scholar
• Yi SA, Nam KH, Kim S, et al. Vulpinic acid controls stem cell fate toward osteogenesis and adipogenesis. Genes (Basel). 2019;11(1):18.
   Google Scholar
• Xu H, Di Antonio M, McKinney S, et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nat Commun. 2017;8:14432.
   Google Scholar
• Hernandez-Verdun D, Roussel P, Thiry M, et al. The nucleolus: structure/function relationship in RNA metabolism. Wiley Interdiscip Rev RNA. 2010;1:415–431.
   Google Scholar
• Peltonen K, Colis L, Liu H, et al. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One. 2010;5:e12996.
   Google Scholar
• Soundararajan S, Chen W, Spicer EK, et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68:2358–2365.
   Google Scholar
• Di Matteo A, Franceschini M, Chiarella S, et al. Molecules that target nucleophosmin for cancer treatment: an update. Oncotarget. 2016;7:44821–44840.
   Google Scholar
• Rathner A, Rathner P, Friedrich A, et al. Drug development for target ribosomal protein rpL35/uL29 for repair of LAMB3R635X in rare skin disease epidermolysis bullosa. Skin Pharmacol Physiol. 2021;6:1–16.
   Google Scholar
• Alter BP, Giri N, Savage SA, et al. Cancer in dyskeratosis congenita. Blood. 2009;113(26):6549–6557. https://medlineplus.gov/genetics/condition/dyskeratosis-congenita
   Google Scholar
• Baran I, Nalcaci R, Kocak M. Dyskeratosis congenita: clinical report and review of the literature. Int J Dent Hyg. 2010;8(1):68–74.
   Google Scholar
• Keller RB, Gagne KE, Usmani GN, et al. CTC1 Mutations in a patient with dyskeratosis congenita. Pediatr Blood Cancer. 2012;59(2):311–314.
   Google Scholar
• Le Guen T, Jullien L, Touzot F, et al. Human RTEL1 deficiency causes hoyeraal-hreidarsson syndrome with short telomeres and genome instability. Hum Mol Genet. 2013;22(16):3239–3249.
   Google Scholar
• Ganapathi KA, Shimamura A. Ribosomal dysfunction and inherited marrow failure. Br J Haematol. 2008;141(3):376–387.
   Google Scholar
• Martin AN, Li Y. RNase MRP RNA and human genetic diseases. Cell Res. 2007;17(3):219–226.
   Google Scholar
• Matesic D, Hagan JB. Cartilage-hair hypoplasia. Mayo Clin Proc. 2007;82(6):655.
   Google Scholar
• Mattijssen S, Welting TJ, Pruijn GJ. RNase MRP and disease. Wiley Interdiscip Rev RNA. 2010;1(1):102–116. https://medlineplus.gov/genetics/condition/cartilage-hair-hypoplasia
   Google Scholar
• Lafontaine DL. Noncoding RNAs in eukaryotic ribosome biogenesis and function. Nat Struct Mol Biol. 2015;22:11–19.
   Google Scholar